JPRN-UMIN000005362Completed未知
Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by non-steroidal anti-inflammatory drugs(NSAIDs). - Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by NSAIDs.
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine0 sites13 target enrollmentStarted: April 1, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 13
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 70years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients treated with mesalazine or salicylic acid 2 weeks proior to the entry of this study. Patients with escalating the dose of anti-rheumatoid arthritis drugs such as aspirins or proton pump inhitors. Patients took gastroprotective agents such as rebamipide, ecabet sodium, misoprostol. Patients being treated with high-dose corticosteroids (more than 15 mg/day of prednisolone. Patients treated with biologics 90 days prior to the entry of this study. Patients who were allergic to or suffered from side effects by mesalazine of salicylic acids. Patients incapable of swallowing capsule endoscopy. Patients suspicious of intestinal strictures. Patients with malignancies. Pregnancy or possible pregnancy. Patients with side effects by other previous clinical studies. Patients who were considered unsuitable for this study by doctors.
Investigators
Similar Trials
Completed
Phase 2
Mesalazine in chronic idiopathic urticariaChronic Idiopathic urticaria.Idiopathic UrticariaIRCT138710041520N1Shiraz University of Medical Sciences - Vice Chancellor for Research Affairs30
Active, not recruiting
Not Applicable
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
Active, not recruiting
Phase 1
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136
Completed
Phase 3
Clinical efficacy of Mesalazine in patients with diarrhea-dominant irritable bowel syndrome with elevated fecal calprotectin referred to Emam Reza Hospital of Tabriz: a randomized double-blind, placebo-controlled trialIrritable Bowel Syndrome.Irritable bowel syndromeIRCT20151106024901N5Tabriz University of Medical Sciences90
Completed
Phase 3
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.Ulcerative ColitisNCT00737789Ferring Pharmaceuticals206